THAC announces the acquisition of an international patent on its drug candidate ALF-5755 for the early treatment of type 2 diabetes mellitus and relating to the composition of the gut microbiota


PARIS & TAMPA, Florida – (COMMERCIAL THREAD) –THAC SA (The Healthy Aging Company), a biopharmaceutical company that is developing a new class of drugs for the early treatment of type 2 diabetes (T2DM), announces the acquisition of an international patent filed by INSERM, Hôpitaux de Paris, l ‘INRA and the University of Paris. This patent protects the drug candidate from THAC and its use for the protection of oxygen-sensitive bacteria, for example in the gut microbiota. The Company reserves the right to submit a divisional application in the coming months.

“Our drug candidate, by acting directly on the human microbiota and by attacking insulin resistance as the root cause of T2DM, has real potential to modify the progression of the disease and be a game-changer for patient care. . according to Professor Christian Bréchot, co-founder and Chairman of the Board of Directors of the Company.

“This acquisition is essential for the growth of the Company. It helps strengthen our solid patent portfolio as well as develop a competitive oral formulation for our product. With this patent, we are accelerating our development, and we are strengthening our competitive position in the market. The axis of the microbiota and T2D is very promising for finally stopping and curing the disease ” describes Lyse Santoro, CEO of the Company.

The “First in Class” drug candidate developed by the Company incorporates the active ingredient ALF-5755. It is a recombinant protein derived from a human antimicrobial protein that contributes to the innate enteric immune system and determines the balance between pathogens and commensal bacteria in the microbiota while maintaining the integrity of the intestinal wall. This direct action on the composition of the microbiota reinforces the unique and innovative mode of action of ALF-5755 to fight against insulin resistance responsible for high blood sugar in T2DM patients.

Dysbiosis, an imbalance of the intestinal flora in humans, is characterized by complex modifications of the microbiota and its various microorganisms. Strong experimental data demonstrate that intestinal dysbiosis is associated with the pathogenesis of many human diseases, including intestinal and metabolic diseases such as obesity and type 2 diabetes. Indeed, dysbiosis impairs the integrity of the human body. intestinal wall and results in the production of metabolites that affect insulin sensitization.

Type 2 diabetes mellitus is the world’s first non-infectious pandemic and represents an enormous medical and economic burden with strong consequences for patients, professionals, health organizations and states. Pandemics of T2DM also contribute to an increase in morbidity in the context of infectious diseases, such as Covid19. Despite the recent progress made in the care of patients with T2DM, the World Health Organization warns of a real unmet medical need and claims the need to develop new drugs capable of modifying or even stopping the progression of the disease by fighting against insulin resistance, at the origin of the disease. Thanks to the unique and innovative mode of action of the active substance ALF-5755, THAC’s drug candidates tackle insulin resistance with real disease-modifying potential while ensuring a long-term safety profile. term and preventing side effects and complications. The aim is to stem global pandemics, improve the quality of life of patients, and reduce costs related to pre-mortality and health care.

About THAC (The Healthy Aging Company)

THAC is a private biopharmaceutical company whose ambition is to improve patient care for healthy aging by targeting age-related diseases and focusing first on type 2 diabetes (T2DM) ) for which there is still a huge unmet medical need claimed by the World Health Organization and the European and American Diabetes Associations (EADS, ADA), despite recent progress. THAC aims to stem the progression of T2DM (the first non-infectious global pandemic) with a disease-modifying drug, and to be a game-changer in patient care. In this context, THAC is accelerating its development by entering the clinical phase.

The Company is anchored on solid scientific expertise and exceptional achievements. THAC is located in Paris (Cochin Hospital and University of Paris) and in the United States (University of South Florida). Several international scientific articles published in peer-reviewed journals as well as a strong portfolio of international patents underline the quality of science and innovation within the Company.

The Company’s mission is to develop a First in Class drug candidate to fight against insulin resistance, which is at the origin of the disease, by a systemic effect as well as by a direct action on the intestinal microbiota. THAC drugs will alter the progression of the disease and prevent serious complications associated with it (such as neuropathy and diabetic sores). Beyond T2DM, the drug candidate also has the potential to prevent age-related diseases and enable healthy aging.

THAC is owned by seasoned and respected Founders and Board Members. Professor Christian Bréchot, CEO of the National Institute of Health for Research in France (INSERM) and CEO of the French Pasteur Institute throughout his professional career, is now a professor at the University of South Florida and president of the Global Virus Network. He is currently President of the Company. Dr Gilles Amouyal, Dr Paul Amouyal, Professor Christophe Magnan and Laure Jamot (PhD) are co-founders and members of the board of directors. Mr. Jean-Philippe Santoni is an independent director of THAC after a brilliant career at Sanofi at the head of R&D. Finally, Lyse Santoro joined the company in October 2020 as CEO of the company and member of the board of directors. She has an experienced and diverse professional background, both in the public sector and in industry in various operational and strategic positions. She has 10 years of experience in biotech / medtech management. She was mandated by the French government as a qualified person to lead the work of the Strategic Council for Health Industries (CSIS 2021) leading to a Health Innovation Plan announced by Mr. Emmanuel Macron, President of the Republic with 7 billion euros dedicated to innovation in healthcare. http://www.thac.fr

LinkedIn

Twitter


About Alma Ackerman

Check Also

Economic reforms imperative for economic stability and growth | Print edition

Views) : The main concern of the government and the concern of the people are …

Leave a Reply

Your email address will not be published.